ADMA Biologics, Inc. (ADMA) |
|
3.255 0.015 (0.46%)
|
12-06 10:19 |
|
Open: |
3.23 |
Pre. Close: |
3.24 |
|
High:
|
3.27 |
Low:
|
3.18 |
|
Volume:
|
368,855 |
Market Cap:
|
641(M) |
|
|
|
Technical analysis |
as of: 2022-12-06 9:45:41 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 4.05 One year: 4.73 |
| Support: |
Support1: 2.85 Support2: 2.47 |
| Resistance: |
Resistance1: 3.47 Resistance2: 4.05 |
| Pivot: |
3.23  |
| Moving Average: |
MA(5): 3.28 MA(20): 3.16 
MA(100): 2.63 MA(250): 2.11 |
| MACD: |
MACD(12,26): 0.1 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 55.3 %D(3): 64.7 |
| RSI: |
RSI(14): 57.9 |
| 52-week: |
High: 3.47 Low: 1.16 |
| Average Vol(K): |
3-Month: 3,077 (K) 10-Days: 2,362 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ADMA ] has closed below upper band by 44.5%. Bollinger Bands are 51.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.4 - 3.42 |
3.42 - 3.44 |
|
Low:
|
3.18 - 3.2 |
3.2 - 3.21 |
|
Close:
|
3.21 - 3.24 |
3.24 - 3.26 |
|
Company Description |
|
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. |
Headline News |
Mon, 05 Dec 2022
Arginine metabolites linked to smoking related periodontitis - Medical Dialogues
Sun, 04 Dec 2022
Perspective - Andrea Martens at ADMA and the biggest year of change - AdNews
Fri, 02 Dec 2022
The effect of haptoglobin genotype on the association of asymmetric dimethylarginine and DDAH 1 polymorphism with diabetic macroangiopathy - Cardiovascular Diabetology - Cardiovascular Diabetology
Thu, 01 Dec 2022
ADMA Biologics Inc (ADMA) is up 3.80% in a Week, Should You Sell? - InvestorsObserver
Thu, 01 Dec 2022
NAB's Suzana Ristevski on her team's key learnings from ADMA - Mediaweek
Mon, 21 Nov 2022
Where Does ADMA Biologics Inc (ADMA) Stock Fall in the Biotechnology Field After It Is Lower By -4.23% This Week? - InvestorsObserver
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
197 (M) |
| Shares Float |
171 (M) |
|
% Held by Insiders
|
2 (%) |
|
% Held by Institutions
|
80 (%) |
|
Shares Short
|
25,860 (K) |
|
Shares Short P.Month
|
27,560 (K) |
Stock Financials |
|
EPS
|
-0.5 |
|
EPS Est Next Qtl
|
-0.38 |
|
EPS Est This Year
|
-1.75 |
|
EPS Est Next Year
|
-1.09 |
|
Book Value (p.s.)
|
0.5 |
|
Profit Margin (%)
|
-53.9 |
|
Operating Margin (%)
|
-35.7 |
|
Return on Assets (ttm)
|
-10.8 |
|
Return on Equity (ttm)
|
-69.3 |
|
Qtrly Rev. Growth
|
98.6 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0.66 |
|
EBITDA (p.s.)
|
-0.21 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-86 (M) |
|
Levered Free Cash Flow
|
-76 (M) |
Stock Valuations |
|
PE Ratio
|
-6.63 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
6.36 |
|
Price to Sales
|
4.89 |
|
Price to Cash Flow
|
-7.47 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
